Passive immunotherapy of viral infections: 'super-antibodies' enter the fray

Laura M. Walker[1] and **Dennis R. Burton**[2,3,4]

[1]Adimab LLC, Lebanon, New Hampshire 03766, USA

[2]Department of Immunology and Microbiology, Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California 92037, USA

[3]International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California 92037, USA

[4]Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts 02139, USA

Abstract

Antibodies have been used for more than 100 years in the therapy of infectious diseases but a new generation of highly potent and/or broadly cross-reactive human monoclonal antibodies (sometimes referred to as 'super-antibodies') offers new opportunities for intervention. The isolation of these antibodies, which are often rarely induced in human infections, has primarily been achieved by large-scale screening for suitable donors and new single B cell approaches to human monoclonal antibody generation. Engineering the antibodies to improve half-life and effector functions has further augmented their *in vivo* activity in some cases. Super-antibodies

Correspondence to L. M. W. or D. R. B. laura.walker@adimab.com; burton@scripps.edu.

FURTHER READING

The AMP study: https://ampstudy.org/about

Competing interests

The authors have no competing interests.

Author contributions

Both authors contributed to research and discussion of content of the article, and to writing, reviewing and editing of the manuscript before submission.

ONLINE

1. Antibodies have been used for over a century prophylactically and, less often, therapeutically against viruses.

2. "Super-antibodies" — a new generation of highly potent and/or broadly cross-reactive human monoclonal antibodies — offer new opportunities for prophylaxis and therapy of viral infections.

3. Super-antibodies are typically generated in natural infection infrequently and/or in a limited number of individuals.

4. Isolation of these antibodies has primarily been achieved by large-scale screening for suitable donors and new single B cell approaches to human monoclonal antibody generation.

5. Super-antibodies may offer the possibility of treating multiple viruses of a given family with single reagents. They are also valuable templates for rational vaccine design.

6. The great potency of super-antibodies has many advantages for practical development as therapeutic reagents. These advantages can be enhanced by a variety of antibody engineering technologies.

Subject categories

Biological sciences/Immunology/Infectious diseases/Viral infection [URI/631/250/255/2514]
Biological sciences/Biotechnology/Biologics/Antibody therapy [URI/631/61/51/1568]

offer promise for the prophylaxis and therapy of infections with a range of viruses, including those that are highly antigenically variable and those that are newly emerging or have pandemic potential. The next few years will be decisive in the realization of the promise of super-antibodies.

TOC blurb

So-called 'super-antibodies' are highly potent, broadly reactive antiviral antibodies that offer promise for the treatment of various chronic and emerging viruses. This Review describes how recent technological advances led to their isolation from rare infected individuals and their development for the prevention and treatment of various viral infections.

The use of antibodies to ameliorate the adverse clinical effects of microbial infection can be traced back to the late nineteenth century and the work of von Behring and Kitasato on serum therapy of diphtheria and tetanus (reviewed in REFS [1,2]). In these settings, the antibodies act to neutralize bacterial toxins. Therapies followed in which serum antibodies were targeted directly against bacterial and then viral pathogens. For viral pathogens, enriched polyclonal IgG molecules from immunized animals were shown to be effective in prophylaxis, and even post-exposure prophylaxis, for a number of viruses including hepatitis A virus, hepatitis B virus, hepatitis C virus, herpes simplex virus, measles virus, rabies virus, respiratory syncytial virus (RSV), smallpox virus and varicella zoster virus. Generally, the efficacy of antibody preparations declined with the duration of infection such that they were often regarded as poor therapeutic options. Of course, the major antiviral strategy of the twentieth century was vaccination.

Over the latter part of the twentieth and early part of the twenty-first century, there have been major developments in our understanding of and ability to manipulate antibodies. The advent of hybridoma technology in 1976 provided a reliable source of mouse monoclonal antibodies (mAbs), the first impact of which was not on antibody therapy but on the characterization of cells through the definition of cell surface markers. Broad implementation of mAbs in therapy had to wait until the development of humanized mouse antibodies and then the generation of fully human antibodies by various techniques described below. Such antibodies have been largely applied in the fields of oncology and autoimmunity. Only a single antiviral mAbs, the RSV-specific antibody palivizumab, is in widespread clinical use. The reasons for this have been discussed elsewhere[1,3–6], although perhaps the most significant reasons are the relatively high cost of production of mAbs, the difficulties of administration and a belief that antibodies are largely only effective in a prophylactic setting, which can be achieved for many viruses by vaccination.

However, as we discuss here, an increasing number of antiviral antibodies with quite remarkable properties in terms of potency and/or cross-reactivity with other viruses or strains of the same virus are being isolated. These so-called 'super-antibodies' are changing our understanding of what we can hope to achieve with antibodies against microbial infection in the clinic. Increased potency can greatly reduce the unit costs of treatment, make feasible alternative routes of administration and extend the effective half-life of the antibody. Increased cross-reactivity can allow us to consider targeting multiple viruses with single

antibodies. Antibody engineering can impact both potency and cross-reactivity and can greatly extend half-life of super-antibodies.

In this Review, we discuss how new approaches have fueled the identification of super-antibodies, where and how such antibodies may be best applied and future directions for the field.

Super-antibody discovery

Many acute viral infections induce robust neutralizing antibody responses in the large majority of individuals. In general, these viruses show little evidence for evasion of antibody responses and we have referred to them as 'evasion lite' [7]. Typically, they either display limited antigenic variability in their surface protein (or proteins) or they show considerable variability but nevertheless express immunodominant conserved epitopes. Examples of viruses in this category include measles virus, poliovirus, chikungunya virus and RSV[8–11]. Presumably the life cycle of these viruses does not dictate immune evasion. For these types of viruses, the isolation of super-antibodies from immune donors has been achieved in a relatively straightforward manner[8,9,12–14]. However, some viruses have evolved mechanisms to evade effective neutralizing antibody responses (termed 'evasion strong') and induce such responses at much lower levels. Effective responses in the context of infection with highly antigenically variable viruses refers not only to their neutralization potency but also to their effectiveness against diverse circulating global isolates, often referred to as breadth. For these viruses —including HIV, influenza virus, Ebola virus and Lassa virus — only a proportion of infected individuals, sometimes quite small, will generate broad and potent neutralizing antibody responses[15–21]. Furthermore, within these individuals, potent broadly neutralizing antibody (bnAb) specificities generally only constitute a small fraction of the antigen-specific memory B cell pool.

For example, only a few percent of HIV-1-infected individuals develop broad and potent serum responses over time, and B cell cloning efforts have demonstrated that bnAbs generally comprise <1% of the HIV envelope (Env)-specific memory B cell repertoire[22]. Although there are probably multiple factors that contribute to the low abundance of bnAbs within these individuals, the intrinsic nature of the viral Env protein likely has a key role. The HIV Env protein has evolved a multitude of mechanisms to evade bnAb responses, including decoy forms of Env, enormous antigenic variability, an evolving glycan shield, immunodominant variable epitopes, and poorly accessible conserved epitopes[23]. Furthermore, most HIV-specific bnAbs incorporate unusual features for epitope recognition, such as uncommonly long (or short) complementarity determining region 3 (CDR3) loops, insertions and deletions, tyrosine sulfation and extensive somatic hypermutation, which likely also contribute to the rarity and delayed development of bnAbs during natural infection[24–26].

In the case of influenza virus infection, the vast majority of neutralizing antibodies elicited by infection or vaccination bind to variable epitopes within the haemagglutinin (HA) globular head of the viral particles and display strain-specific neutralizing activity[27]. Influenza virus-specific bnAbs typically target the conserved HA stem, but this region has

variable immunogenicity[28–31]. The relatively low frequency of bnAbs against the HA stem is perhaps due to the typically tight packing of HA trimers on the virus surface, which may limit antibody accessibility to this region. For Ebola and Lassa viruses, extensive glycosylation on the surface envelope proteins results in masking of conserved neutralizing epitopes[15,32]. In cases where super-antibodies are present at low frequency within immune repertoires, large-scale donor screening and high-throughput B cell isolation platforms have proven to be critical for the discovery of super-antibodies. Over the past several years, technological advances in these two areas have led to the identification large numbers of super-antibodies, mostly from infected individuals, against a plethora of viral pathogens.

Large-scale donor screening

In the case of HIV, which has served as a prototype virus for many studies in this field [33], systematic selection of donors with broadly neutralizing serum responses has proven to be critical for the identification of super-antibodies. Prior to 2009, the HIV field had been operating with a handful of bnAbs, all of which were limited either in breadth or in potency [34]. A number of factors complicated the identification of bnAbs, including the inefficiency of traditional approaches to mAb discovery, the small fraction of B cells that secrete bnAbs, and the limited availability of samples from donors who had developed broad and potent neutralizing serum responses. Beginning in 2005, the problem of limited samples was addressed by establishing donor screening programmes to identify HIV-infected individuals with broadly neutralizing serum responses to serve as source material for the generation of bnAbs[18,19,35,36]. In one of the largest studies, ~1,800 HIV-1-infected individuals from Australia, Rwanda, Uganda, the United Kingdom and Zambia were screened for broadly neutralizing sera using a reduced pseudovirus panel representative of global circulating HIV-1 isolates[19]. A subset of individuals, termed "elite neutralizers", were identified that exhibited exceptionally broad and potent neutralizing serum responses and were therefore prioritized for bnAb isolation.

Over the past eight years, mining of these and similar samples has led to the identification of dozens of remarkably broad and potent HIV super-antibodies[37–41]. Careful selection of donors with desirable serum profiles has also enabled the isolation of rare super-antibodies to influenza virus, RSV, human metapneumovirus (HMPV), rabies virus and Zika virus[12,42–44]. For example, the pan-influenza A virus-neutralizing mAb FI6 and the RSV and HMPV cross-neutralizing mAb MPE8 were isolated from donors who were selected on the basis of their strong heterotypic serum responses[12,42]. Similarly, two pan-lyssavirus neutralizing mAbs, called RVC20 and RVC58, were isolated from the memory B cells of four donors who exhibited potent serum neutralizing activity against multiple lyssavirus species[43].

High-throughput human B cell isolation technologies

Human antiviral neutralizing mAbs have been isolated using various different technologies, including combinatorial display libraries, human immunoglobulin transgenic mice and single B cell isolation methods (Fig. 1). Although all of these technologies have proven valuable for mAb generation, the recent burst in super-antibody discovery has primarily been driven by advances in single B cell-based methods. There are several possible reasons

for this, including inefficiencies in combinatorial library generation and interrogation (leading to the loss of rare clones), altered binding characteristics of antibody fragments produced in heterologous expression systems (for example, *Escherichia coli* or yeast), constraints on the generation of suitable recombinant antigens for immunization or library selections, the loss of native heavy and light chain pairing during immune library generation, and inherent differences between the adaptive immune systems of humanized mice and humans[45].

Over the past decade, several technological breakthroughs in the B cell cloning arena have fueled super-antibody identification. One of these advances came in 2009, when direct functional screening of thousands of B cell clones from an HIV elite neutralizer led to the isolation of two super-antibodies, PG9 and PG16, which were about an order of magnitude more potent than first-generation bnAbs[37]. Notably, PG9 and PG16 bind poorly to recombinant Env proteins and thus would not have been identified without direct functional screening of B cell supernatants. To date, many dozens of HIV-specific bnAbs targeting a diverse range of epitopes have been identified using functional screening approaches[39,46–48]. Highly potent super-antibodies to RSV, HMPV, Lassa virus and human cytomegalovirus (HCMV) have also been discovered using high-throughput functional screening technologies[12,13,49,50] (Table 1).

Similar to PG9 and PG16, these super-antibodies were isolated by screening B cell supernatants based on their capacity to neutralize infection *in vitro* and were subsequently found to react poorly with currently available recombinant envelope proteins. In the case of RSV, this approach led to the isolation of the highly potent mAb D25, which binds to an epitope that is exclusively expressed on the prefusion conformation of RSV fusion (F) glycoprotein[49,51]. An engineered variant of mAb D25 (MEDI8897), which exhibits 50–100 times greater neutralization potency than palivizumab, is now being tested in clinical trials for the prevention of RSV-associated disease in high-risk infants. A second RSV prefusion F-specific super-antibody, which cross-neutralizes several different paramyxoviruses including HMPV, was also isolated by screening B cell supernatants for neutralizing activity[12] (Table 1).

In the case of HCMV, direct functional screening enabled the isolation of highly potent super-antibodies specific for conformational epitopes within the gH–gL–UL128–UL130–UL131A pentamer complex, which was not previously known to be a target for neutralizing antibodies[13]. Direct functional screening approaches have also led to the discovery of potent super-antibodies to Middle East respiratory syndrome coronavirus (MERS-CoV), Ebola virus, influenza virus, chikungunya virus, rabies virus and the poxvirus family[9,42,43,52–56]. Notably, in the case of MERS-CoV, only a single B cell culture out of 4,600 screened showed neutralizing activity[53]. Similarly, the pan-influenza A virus neutralizing mAb FI6 was isolated by testing 104,000 plasma cells from eight immune donors[42]. Finally, only two out of 500 mAbs that were selected based on their ability to neutralize rabies virus showed cross-neutralizing activity against multiple lyssavirus species[43]. These examples clearly illustrate that exhaustive interrogation of immune repertoires is often required for the identification of rare cross-neutralizing super-antibodies.

A second breakthrough in the HIV antibody field followed the development of technology for antigen-specific single B cell sorting[57–59]. This approach, coupled with the use of rationally designed Env probes, allowed for the discovery of two new potent HIV bnAbs that target the conserved CD4 binding site[60,61] (Table 1). Following this discovery, several other potent bnAbs against the CD4 binding site were isolated using similar approaches[38,62,63]. Recently, advances in the generation of recombinant native-like HIV Env trimers have enabled the identification of exceptionally potent "PG9-class" bnAbs[40].

Many HIV super-antibodies have now been generated using single B cell sorting technology[38,40,60,62,63]. The use of fluorescently labeled probes to sort antigen-specific memory B cells has also allowed for the discovery of highly potent super-antibodies to Ebola virus, RSV, human papilloma virus (HPV), Zika virus and influenza virus[11,30,31,44,64,65]. In the case of Ebola virus, a large-scale single B cell cloning effort led to the isolation of several hundred mAbs specific for Ebola virus surface glycoprotein (GP), two of which showed potent pan-Ebola virus neutralizing activity and protective efficacy[64,66]. A similar effort in the RSV field allowed for the isolation of several prefusion F protein-specific mAbs that show over 100 times more potent neutralizing activity than palivizumab[11]. In addition, multiple groups have used clever dual antigen labeling strategies to identify potent bnAbs to HIV, influenza virus, Ebola virus and HPV[30,31,40,65,67,68]. The structures of several super-antibodies bound to their viral targets are shown in Fig 2. Finally, a recent report showed that bnAbs to HIV can be readily elicited in cows using a single Env trimer immunogen and that this induction depends on the long heavy chain CDR3 loops of the bovine immunoglobulin repertoire [67]. It is possible that this repertoire may provide advantages in generating super-antibodies against other pathogens.

Vaccination or infection-induced antibody-secreting cell (ASC) responses have also proven to be a rich source of antigen-specific antibodies. Following early studies that showed a transient but large population of ASCs appears in peripheral blood 5–7 days after tetanus toxoid booster vaccination [69], it was shown that influenza virus vaccination produced a similar ASC response and that the large majority of mAbs cloned from these cells bound with high affinity to influenza virus, providing a proof-of-concept that the ASC response could be exploited to rapidly generate antigen-specific antibodies against any immunizing antigen [70]. To date, plasmablast cloning has led to the isolation of mAbs against many different viruses, including dengue virus, Zika virus, HIV, influenza virus, vaccinia virus and rotavirus[29,71–76].

One of the advantages of the plasmablast approach is that antigen baiting is not required for B cell sorting, thereby allowing for the isolation of antibodies that target epitopes that are poorly expressed on recombinant antigens. For example, in the case of dengue virus, potent bnAbs targeting E-dimer dependent epitopes were isolated using this approach[72]. However, it is important to emphasize that the ability to isolate super-antibodies using this method will depend on several factors. First, during a primary infection, the ASC population will be mainly composed of activated, low-affinity naive B cells (rather than affinity-matured memory B cells), making the possibility of identifying super-antibodies extremely unlikely. Second, in the context of a booster vaccination or secondary infection with an antigenically similar virus, most of the plasmablast response will be directed against immunodominant

epitopes, which in many cases are not targeted by effective neutralizing antibodies. In such cases, exhaustive cloning, production and characterization of the plasmablast-derived mAbs would likely be required to identify rare super-antibodies. In contrast, secondary infection with an antigenically related but sufficiently divergent virus can drive the preferential expansion of B cells that target highly conserved epitopes, as exemplified by the unusually high frequency of bnAbs induced in donors who were infected with the novel H1N1 influenza virus in 2009[29,75]. In principle, one could use this type of approach for the generation of super-antibodies in humanized mice or other animal models using suitably designed immunogens and immunization regimens.

Rapid response platforms for emerging viruses

Over the past two decades, humanity has faced a new emerging, or re-emerging, viral threat almost every year, including severe acute respiratory syndrome coronavirus (SARS), West Nile virus, pandemic influenza virus, Ebola virus, MERS-CoV and Zika virus. Due to their comparatively fast path to approval and generally favourable safety profiles, mAb therapies represent a promising alternative to vaccines and small molecule drugs for the treatment and prevention of emerging viral threats. Recently, several laboratories have demonstrated the feasibility of identifying, characterizing and scaling-up production of highly potent mAbs in remarkably short timeframes.

In response to the 2014–2015 MERS-CoV outbreak, two different groups illustrated the power of their mAb discovery platforms by isolating highly potent MERS-specific mAbs, producing the mAbs in gram quantities, and testing the lead mAbs in animal models at an unprecedented speed[53,77]. In one of these studies, a single highly potent MERS-CoV neutralizing mAb was identified from the memory B cells of a convalescent donor using a high-throughput functional screening approach[53]. This mAb, called LCA60, showed both pre- and post-exposure protection in a mouse model of MERS-CoV infection. Importantly, it only took the authors four months from the initial B cell screening to the development of a stable cell line that produces the neutralizing mAb at 5 g/L. In the second study, human immunoglobulin transgenic mice were immunized with the MERS-CoV Spike protein and then used to generate a panel of potent MER-CoV-specific neutralizing mAbs within several weeks[77]. The authors also quickly generated a humanized mouse model of MERS-CoV infection, which was used to demonstrate the therapeutic efficacy of their mAbs.

In a third study, vaccination of transchromosomal cows engineered to produce fully human IgG molecules with MERS-CoV was shown to yield high serum titres of MERS-CoV-specific neutralizing antibodies[78]. Importantly, administration of the purified polyclonal transchromosomal bovine human IgG to mice either 12 hours before or 24 and 48 hours after MERS-CoV infection resulted in a significant reduction in viral lung titres. Transchromosomal bovines have also been used to rapidly generate polyclonal neutralizing antibodies to Hanta virus, Venezuelan equine encephalitis virus and Ebola virus[79–81], demonstrating the feasibility of using this platform to rapidly generate therapeutics to combat emerging viral threats. The antibodies arising from transchromosomal cows are polyclonal to date but there is potential for mAb isolation.

Between 2015 and 2016, several groups responded to the 2014–2015 Ebola virus outbreak by swiftly generating highly potent Ebola virus GP-specific neutralizing mAbs from the memory B cells of convalescent donors[54–56,64,66]. Many of these mAbs showed potent post-exposure therapeutic efficacy against either Ebola or Bundibugyo virus in animal models and a subset showed protective efficacy against multiple Ebola virus strains[54,55,64,66]. Similarly, several groups have recently reported on the isolation of potent Zika virus-specific neutralizing mAbs from human donors[14,44,82,83]. Notably, one of these neutralizing mAbs, called ZIKV-117, showed post-exposure protection against Zika virus in both pregnant and non-pregnant mice[82].

In certain cases, the availability of super-antibodies that target highly conserved epitopes may shorten timelines further by bypassing the need for mAb discovery. For example, it was recently shown that a subset of dengue virus-specific mAbs potently cross-neutralize Zika virus[84–86]. These bnAbs — perhaps carrying Fc mutations that ablate Fc receptor binding to avoid potential for antibody-dependent enhancement[14] — could immediately be used for prophylaxis for pregnant women living in Zika virus endemic regions. Notably, cocktails of super-antibodies targeting different epitopes, or bispecific or trispecific super-antibody constructs, will likely be required to prevent neutralization escape[87–93].

Antibodies in prophylaxis and therapy

Antibodies can function against viruses by several mechanisms, primarily divided into activities against free virus particles and activities against infected cells. Neutralization, measured *in vitro* as the ability of antibody to prevent viral entry into target cells without a requirement for involvement of any other agents, is an activity against free virions that has been most correlated with protection *in vivo*. Activities against infected cells generally depend on Fc effector functions and involve host effector cells. They include antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP). It is presumed that these latter activities are likely to be important in therapy using antibodies. Since neutralization frequently correlates with the ability to bind to native structures on the virion surface, it can give some indication of the ability of antibodies to mediate effector activities such as ADCC and ADCP. The potency of super-antibodies is then often estimated from neutralization measurements, although ultimately it is of course *in vivo* activity that is crucial.

Prophylaxis

Vaccination is the most effective and low-cost method of preventing viral disease. However, the development of effective vaccines against many important viral pathogens — including HIV, RSV, hepatitis C virus, dengue virus and HCMV — has been met with limited success. Furthermore, vaccine development is a long complex process, often lasting 10–15 years, making immunization an impractical means of protecting individuals from new emerging viral threats, unless pan-virus family vaccines can be developed. For example, if antibodies can be identified that potently neutralize existing strains of Ebola virus, or even Ebola and Marburg filoviruses, then one could anticipate that a vaccine templated from the antibodies would be effective even against emerging strains of Ebola virus. However, at the current

time, passive antibody prophylaxis represents a promising alternative to vaccination for a number of viral infections.

Currently, three purified polyclonal hyperimmune globulins derived from human donors immune to hepatitis B virus, HCMV or varicella zoster virus are on the market for the prevention of serious diseases associated with these viruses. A rabies virus-specific immune globulin, combined with vaccination, is also available for post-exposure prophylaxis. In 1998, palivizumab — a humanized mAb that targets the RSV F protein — became the first US Food and Drug Administration approved antiviral mAb. Palivizumab soon replaced RSV hyperimmune globulin (RespiGam) for the prevention of severe RSV-associated disease in high-risk infants. However, although palivizumab is more specific and 50–100 times more potent than RespiGam, the cost associated with the required dosing makes its use impractical for all infants[94]. A second-generation RSV-specific mAb, which shows up to 50 times greater neutralization potency than palivizumab and contains substitutions in the Fc domain that extend its serum half-life, is currently in phase 2 clinical trials for the prevention of severe RSV-associated disease in all infants[95] (Table 2).

Although palivizumab is the only commercially available mAb for the prevention of a viral disease, there are multiple antiviral mAbs in preclinical and clinical development that have shown pre-exposure efficacy in animal models. For example, the potent MERS-CoV-specific mAbs described above were shown to prophylactically protect humanized mice against MERS-associated disease. Similarly, mAbs to chikungunya virus, influenza virus, HIV and Ebola virus have shown potent prophylactic efficacy in animal models[9,85,96–102]. Recently, a broadly neutralizing anti-Zika virus mAb (ZIKV-117) was shown to protect against maternal-fetal transmission in a mouse model of Zika virus infection[82]. If this observation translates to humans, prophylaxis with ZIKV-117 or similar neutralizing mAbs may be a promising means of protecting at-risk pregnant women against Zika virus infection and fetal transmission.

In the case of HIV, multiple studies have shown that passively administered neutralizing mAbs provide protection against intravenous, vaginal, rectal and oral challenge in non-human primate and mouse models[99–101,103–106]. A large ongoing study (the antibody mediated prevention (AMP) study) will assess the ability of the VRC01 mAb specific for the CD4 binding site to decrease the risk of HIV acquisition in humans (See Further reading). Although animal studies have provided proof-of-principle that a vaccine capable of inducing sufficient titres of bnAbs could prevent the establishment of HIV infection in humans, and the AMP study will investigate this directly, the design of immunogens that efficiently elicit these rare antibodies remains a formidable challenge. To bypass the challenges associated with active vaccination against HIV, a number of groups have proposed alternative strategies based on vector-mediated antibody gene transfer to express bnAbs *in vivo*[107]. Unlike traditional passive immunization, which would require long-term repeated treatment with bnAbs, vectored immunoprophylaxis only involves a single injection and enables continuous and sustained delivery of antibodies. In 2009, pioneering work demonstrated that vector-mediated delivery of antibody-like molecules can provide vaccine-like protection against SIV challenge in non-human primate models[108].

Subsequent studies have shown that vectored immunoprophylaxis is also compatible with full-length IgG molecules and CD4-like molecules[109–111]. If the preclinical results in mice and macaques translate to humans, vectored antibody gene delivery strategies could provide an alternative form of prophylaxis against HIV and other challenging vaccine targets such as hepatitis C virus, pandemic influenza virus and malaria. Recently, non-viral vector nucleic acid delivery technologies have also been developed to obviate the potential safety issues associated with viral vector-mediated delivery, such as long-term persistence and potential viral DNA integration into the host genome[112–117]. In a recent study, it was shown that the administration of lipid encapsulated, nucleoside-modified mRNAs encoding the heavy and light chain genes of the broadly neutralizing HIV-1-specific antibody VRC01 to humanized mice resulted in high serum antibody concentrations and protection against intravenous HIV-1 challenge[114].

Similar proof-of-concept studies have also been performed using synthetic DNA plasmid-mediated antibody gene transfer[112,113]. In one such study, synthetic DNA plasmids encoding cross-neutralizing anti-dengue virus antibodies were delivered to mice by electroporation and resulted in biologically relevant levels of serum antibody[112]. Importantly, a single intramuscular injection of plasmid DNA conferred protection against severe dengue disease in a mouse model. Although several technical challenges remain to be addressed, such as enhancing *in vivo* antibody expression levels and reducing the potential for immunogenicity, these studies demonstrate the feasibility of using plasmid DNA and modified mRNA-based antibody delivery technologies for passive immunotherapy.

Therapy

Conventional wisdom says that antibodies are effective if present before or shortly after viral exposure but their efficacy declines markedly once infection is established. For example, the anti-RSV antibody palivizumab is effective in the clinic prophylactically but not therapeutically [118]. However, there are indications that the dogma may be challenged by super-antibodies. An example is the ability of a new generation of bnAbs against HIV to strongly impact ongoing infection in animal models [87,119,120], in which an earlier generation of less potent mAbs had very limited effects [121]. This likely reflects the increased neutralization potency of the super-antibodies but also the increased breadth of neutralization that may restrict escape pathways [119]. A number of super-antibodies are now being evaluated in humans for their activities against established HIV infection[122–126] (Table 2). Initial results are interesting, providing for example an indication of enhanced immune responses following bnAb administration [127]. The emerging results will be followed closely, including in the context of combining bnAbs with drugs and other antiviral agents to attempt HIV cure.

For other viruses, clear evidence of a strong therapeutic effect for super-antibodies has not been gathered yet. A number of cases such as antibody treatment of rabies virus and Junin virus infections [43,128] are probably better interpreted as post-exposure prophylaxis rather than therapy of established infection. Two promising examples of possible therapy are the successful treatment of Ebola virus- or Lassa virus-infected monkeys with mAbs once

symptoms have appeared [89,129]. Unfortunately, no definitive evidence of the efficacy of mAbs in Ebola or Lassa-symptomatic humans yet exists.

Camelid-derived single-domain antibodies (sdAbs), which are comprised of a single heavy-chain variable domain, represent a promising new class of antibody-based therapeutics for RSV and other viruses that cause lower respiratory tract infections [130–133]. Due to their small size and high solubility and stability, sdAbs can be rapidly delivered to the site of infection via inhalation. Notably, a neutralizing anti-RSV sdAb (ALX-0171) that targets an epitope overlapping that bound by palivizumab recently showed a trend towards a therapeutic effect in a phase I/IIa clinical trial based on reduced viral loads and clinical symptoms in hospitalized RSV-infected infants. Prefusion F protein-specific sdAbs that show up to 180,000 times greater neutralization potency than ALX-0171 have recently been identified and may offer even greater therapeutic benefit [133].

Practical considerations arising with super-antibodies

Intuitively, the enhanced potency of super-antibodies is immediately recognized as beneficial in antibody prophylaxis and therapy. However, there are also a number of additional effects from this enhanced potency that may not be instantly appreciated and that can be further strengthened by antibody engineering. For example, enhanced potency means that less antibody needs to be used and this can allow easier to develop low-concentration subcutaneous administration, rather than more difficult to develop high-concentration subcutaneous formulations or less convenient (low concentration) intravenous administration. Enhanced potency also means that the life-time of effective antibody following administration is extended, thereby requiring fewer administrations to maintain a useful protective or therapeutic effect. Antibody engineering can also extend half-life significantly [95,134–139] so that for the most potent super-antibodies, one could envisage requiring administrations perhaps only every 3–6 months for efficacy. Antibody engineering can also deliver greater efficacy through enhanced Fc effector function [140,141].

Conclusions

The deployment of antibodies as antiviral agents has progressed through a number of stages over the years, corresponding to increasing levels of potency of the reagent administered. It began with immune serum over a century ago, then to polyclonal antibodies, then mAbs and now into highly potent human mAbs dubbed super-antibodies. Thanks to research that has been primarily carried out in the cancer field, technologies have been developed to endow these super-antibodies with enhanced *in vivo* function.

Will super-antibodies change the landscape of antiviral prophylaxis and therapy? The answer to this question will depend on a number of factors, including, first, the rapidity of development of antiviral vaccines; vaccines will likely remain the cheapest and most effective antiviral measure but some viruses such as HIV present a huge vaccine challenge. Second, the effective cost of antibody treatment, which incorporates not only manufacturing cost but also the durability of administered antibody and the route of administration. Third, the success of antibodies in the treatment of established viral infections. Particularly in the

therapeutic setting, the answers can only be obtained with clinical trials using the best super-antibodies available.

Acknowledgments

GLOSSARY

Humanized mouse antibody

A genetically engineered mouse antibody in which the protein sequence has been modified to increase its similarity to human antibodies, thereby decreasing its potential immunogenicity.

Transchromosomal cows

Cows that have been genetically modified to incorporate human chromosomes so that upon immunization they generate human antibodies.

Antibody-dependent cellular cytotoxicity

A mechanism by which Fc receptor-bearing effector cells such as natural killer (NK) cells recognize and kill antibody-coated target cells, such as virus-infected cells. The Fc portions of the coating antibodies interact with an Fc receptor (e.g. FcγRIII; also known as CD16 that is expressed by NK cells) thereby initiating a signalling cascade that results in the release of 22 cytotoxic granules (containing perforin and granzyme B) from the effector cell, which lead to cell death of the antibody-coated cell.

Complement-dependent cytotoxicity

A mechanism of antibody-mediated immunity whereby the association of antibody on a target cell surface leads to binding of the complement component C1q and triggering of the classical complement cascade. The cascade leads to elimination of taeget cells by a number of mechanisms including the formation of the membrane attack complex, the cytolytic end product of the complement cascade.

Hyperimmune globulins

An antibody preparation generated from the plasma of donors with high titers of antibody against a specific pathogen or antigen. Hyperimmune globulins are available against rabies, hepatitis B and varicella-zoster viruses amongst other viruses.

References

1. Hey A. History and Practice: Antibodies in Infectious Diseases. Microbiol Spectr. 2015; 3 AID-0026-2014.

2. Graham BS, Ambrosino DM. History of passive antibody administration for prevention and treatment of infectious diseases. Curr Opin HIV AIDS. 2015; 10:129–134. An excellent account of the history of passive antibody administration. [PubMed: 25760933]

3. Sparrow E, Friede M, Sheikh M, Torvaldsen S. Therapeutic antibodies for infectious diseases. Bull World Health Organ. 2017; 95:235–237. [PubMed: 28250538]

4. Berry JD, Gaudet RG. Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology. N Biotechnol. 2011; 28:489–501. [PubMed: 21473942]

5. Saylor C, Dadachova E, Casadevall A. Monoclonal antibody-based therapies for microbial diseases. Vaccine. 2009; 27(Suppl 6):G38–46. [PubMed: 20006139]

6. Wilson PC, Andrews SF. Tools to therapeutically harness the human antibody response. Nat Rev Immunol. 2012; 12:709–719. [PubMed: 23007571]

7. Burton DR. What Are the Most Powerful Immunogen Design Vaccine Strategies? Reverse Vaccinology 2.0 Shows Great Promise. Cold Spring Harb Perspect Biol. 2017

8. Chen Z, et al. Cross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptor. Proc Natl Acad Sci U S A. 2013; 110:20242–20247. [PubMed: 24277851]

9. Smith SA, et al. Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus. Cell Host Microbe. 2015; 18:86–95. [PubMed: 26159721]

10. Tahara M, et al. Functional and structural characterization of neutralizing epitopes of measles virus hemagglutinin protein. J Virol. 2013; 87:666–675. [PubMed: 23115278]

11. Gilman MS, et al. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci Immunol. 2016; 1

12. Corti D, et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature. 2013; 501:439–443. One of the first descriptions of a monoclonal antibody with pan-virus type neutralizing ability. [PubMed: 23955151]

13. Macagno A, et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol. 2010; 84:1005–1013. [PubMed: 19889756]

14. Stettler K, et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science. 2016; 353:823–826. [PubMed: 27417494]

15. Sommerstein R, et al. Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection. PLoS Pathog. 2015; 11:e1005276. [PubMed: 26587982]

16. Sather DN, et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol. 2009; 83:757–769. [PubMed: 18987148]

17. Gray ES, et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol. 2011; 85:4828–4840. [PubMed: 21389135]

18. Doria-Rose NA, et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol. 2010; 84:1631–1636. [PubMed: 19923174]

19. Simek MD, et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol. 2009; 83:7337–7348. Describes the assembly and use of a large cohort of HIV-infected individuals with broad neutralizing sera as the starting point for super-antibody generation. [PubMed: 19439467]

20. Jahrling PB, Frame JD, Rhoderick JB, Monson MH. Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. Trans R Soc Trop Med Hyg. 1985; 79:380–384. [PubMed: 3898484]

21. Andrews SF, et al. Immune history profoundly affects broadly protective B cell responses to influenza. Sci Transl Med. 2015; 7:316ra192.

22. Kwong PD, Mascola JR. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity. 2012; 37:412–425. [PubMed: 22999947]

23. Burton DR, Mascola JR. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol. 2015; 16:571–576. [PubMed: 25988889]

24. Kwong PD, Mascola JR, Nabel GJ. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol. 2013; 13:693–701. [PubMed: 23969737]

25. Burton DR, Hangartner L. Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. Annu Rev Immunol. 2016; 34:635–659. [PubMed: 27168247]

26. West AP Jr, et al. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell. 2014; 156:633–648. [PubMed: 24529371]

27. Corti D, Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu Rev Immunol. 2013; 31:705–742. A comprehensive review of broadly neutralizing antibodies against multiple viruses. A comprehensive review of broadly neutralizing antibodies against multiple viruses. [PubMed: 23330954]

28. Li Y, et al. Immune history shapes specificity of pandemic H1N1 influenza antibody responses. J Exp Med. 2013; 210:1493–1500. [PubMed: 23857983]

29. Li GM, et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A. 2012; 109:9047–9052. [PubMed: 22615367]

30. Joyce MG, et al. Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. Cell. 2016; 166:609–623. [PubMed: 27453470]

31. Andrews SF, et al. Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans. Sci Immunol. 2017; 2

32. Lee JE, et al. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature. 2008; 454:177–182. [PubMed: 18615077]

33. Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science. 2012; 337:183–186. [PubMed: 22798606]

34. Burton DR. A vaccine for HIV type 1: the antibody perspective. Proc Natl Acad Sci U S A. 1997; 94:10018–10023. [PubMed: 9294155]

35. Li Y, et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med. 2007; 13:1032–1034. [PubMed: 17721546]

36. Medina-Ramirez M, et al. Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia. J Virol. 2011; 85:5804–5813. [PubMed: 21471239]

37. Walker LM, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009; 326:285–289. The isolation of the first of a new generation of HIV broadly neutralizing antibodies and one of the first super-antibodies. [PubMed: 19729618]

38. Falkowska E, et al. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J Virol. 2012; 86:4394–4403. [PubMed: 22345481]

39. Walker LM, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011; 477:466–470. [PubMed: 21849977]

40. Sok D, et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc Natl Acad Sci U S A. 2014; 111:17624–17629. [PubMed: 25422458]

41. Falkowska E, et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity. 2014; 40:657–668. [PubMed: 24768347]

42. Corti D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011; 333:850–856. Describes a very broad influenza super-antibody of the type that indicates a universal flu vaccine may be possible. [PubMed: 21798894]

43. De Benedictis P, et al. Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis. EMBO Mol Med. 2016; 8:407–421. [PubMed: 26992832]

44. Robbiani DF, et al. Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico. Cell. 2017; 169:597–609 e511. [PubMed: 28475892]

45. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004; 172:2731–2738. [PubMed: 14978070]

46. Bonsignori M, et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol. 2011; 85:9998–10009. [PubMed: 21795340]

47. Huang J, et al. Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. Immunity. 2016; 45:1108–1121. [PubMed: 27851912]

48. Doria-Rose NA, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014; 509:55–62. [PubMed: 24590074]

49. Kwakkenbos MJ, et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med. 2010; 16:123–128. [PubMed: 20023635]

50. Robinson JE, et al. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat Commun. 2016; 7:11544. [PubMed: 27161536]

51. McLellan JS, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013; 340:1113–1117. [PubMed: 23618766]

52. Gilchuk I, et al. Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections. Cell. 2016; 167:684–694 e689. [PubMed: 27768891]

53. Corti D, et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc Natl Acad Sci U S A. 2015; 112:10473–10478. [PubMed: 26216974]

54. Flyak AI, et al. Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection. Cell. 2016; 164:392–405. [PubMed: 26806128]

55. Corti D, et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science. 2016; 351:1339–1342. [PubMed: 26917593]

56. Misasi J, et al. Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science. 2016; 351:1343–1346. [PubMed: 26917592]

57. Babcook JS, Leslie KB, Olsen OA, Salmon RA, Schrader JW. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci U S A. 1996; 93:7843–7848. The first description of single B cell technology for the isolation of multiple monoclonal antibodies. [PubMed: 8755564]

58. Tiller T, et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods. 2008; 329:112–124. Application of single B cell technology to the isolation of human monoclonal antibodies. [PubMed: 17996249]

59. Wardemann H, et al. Predominant autoantibody production by early human B cell precursors. Science. 2003; 301:1374–1377. [PubMed: 12920303]

60. Wu X, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010; 329:856–861. Isolation of the prototype broadly neutralizing super-antibody to the CD4 binding site, VRC01. [PubMed: 20616233]

61. Zhou T, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science. 2010; 329:811–817. [PubMed: 20616231]

62. Scheid JF, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 2011; 333:1633–1637. [PubMed: 21764753]

63. Wu X, et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science. 2011; 333:1593–1602. [PubMed: 21835983]

64. Bornholdt ZA, et al. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science. 2016; 351:1078–1083. Isolation of large numbers of monoclonal antibodies from an Ebola survivor immediately following the outbreak and rapid identification of super-antibodies. [PubMed: 26912366]

65. Scherer EM, et al. Characteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunity. PLoS Pathog. 2014; 10:e1004461. [PubMed: 25330199]

66. Wec AZ, et al. Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. Cell. 2017; 169:878–890 e815. [PubMed: 28525755]

67. Sok D, et al. Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows. Nature. 2017; 548:108–111. Reliable generation of broadly neutralizing HIV antibodies by simple immunization in cows suggesting this animal might have special value in super-antibody generation. [PubMed: 28726771]

68. Zhao X, et al. Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. Cell. 2017; 169:891–904 e815. [PubMed: 28525756]

69. Stevens RH, Macy E, Morrow C, Saxon A. Characterization of a circulating subpopulation of spontaneous antitetanus toxoid antibody producing B cells following in vivo booster immunization. J Immunol. 1979; 122:2498–2504. [PubMed: 312871]

70. Wrammert J, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature. 2008; 453:667–671. Description of a plasmablast approach to super-antibody generation. [PubMed: 18449194]

71. Priyamvada L, et al. B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts. J Virol. 2016; 90:5574–5585. [PubMed: 27030262]

72. Dejnirattisai W, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol. 2015; 16:170–177. [PubMed: 25501631]

73. Nair N, et al. VP4- and VP7-specific antibodies mediate heterotypic immunity to rotavirus in humans. Sci Transl Med. 2017; 9:eaam5434. [PubMed: 28637924]

74. Silveira EL, et al. Vaccine-induced plasmablast responses in rhesus macaques: phenotypic characterization and a source for generating antigen-specific monoclonal antibodies. J Immunol Methods. 2015; 416:69–83. [PubMed: 25445326]

75. Wrammert J, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med. 2011; 208:181–193. [PubMed: 21220454]

76. Rogers TF, et al. Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors. Sci Immunol. 2017 In Press.

77. Pascal KE, et al. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2015; 112:8738–8743. [PubMed: 26124093]

78. Luke T, et al. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci Transl Med. 2016; 8:326ra321.

79. Hooper JW, et al. DNA vaccine-derived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome. Sci Transl Med. 2014; 6:264ra162.

80. Gardner CL, et al. Antibody Preparations from Human Transchromosomic Cows Exhibit Prophylactic and Therapeutic Efficacy against Venezuelan Equine Encephalitis Virus. J Virol. 2017:91.

81. Dye JM, et al. Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle. Sci Rep. 2016; 6:24897. [PubMed: 27109916]

82. Sapparapu G, et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature. 2016; 540:443–447. [PubMed: 27819683]

83. Wang Q, et al. Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Sci Transl Med. 2016; 8:369ra179.

84. Priyamvada L, et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci U S A. 2016; 113:7852–7857. [PubMed: 27354515]

85. Barba-Spaeth G, et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature. 2016; 536:48–53. [PubMed: 27338953]

86. Beltramello M, et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe. 2010; 8:271–283. [PubMed: 20833378]

87. Shingai M, et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature. 2013; 503:277–280. [PubMed: 24172896]

88. Prabakaran M, et al. Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants. PLoS One. 2009; 4:e5672. [PubMed: 19478856]

89. Mire CE, et al. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat Med. 2017; 23:1146–1149. First demonstration in non-human primates that monoclonal antibodies can protect against advanced Lassa fever. [PubMed: 28869611]

90. Magnani DM, et al. Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques. Sci Transl Med. 2017:9.

91. Xu L, et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science. 2017; 358:85–90. Novel design of antibodies to cope with HIV diversity by incorporating three specificities into a single antibody-like molecule. [PubMed: 28931639]

92. Julg B, et al. Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. Sci Transl Med. 2017:9.

93. Wang J, et al. A Human Bi-specific Antibody against Zika Virus with High Therapeutic Potential. Cell. 2017; 171:229–241 e215. [PubMed: 28938115]

94. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998; 102:531–537.

95. Zhu Q, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med. 2017:9. Description of an RSV super-antibody that shows about ten times greater in vivo efficacy than palivizumab in cotton rats.

96. Sui J, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol. 2009; 16:265–273. [PubMed: 19234466]

97. Qiu X, et al. Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl Trop Dis. 2012; 6:e1575. [PubMed: 22448295]

98. Wilson JA, et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science. 2000; 287:1664–1666. [PubMed: 10698744]

99. Mascola JR, et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol. 1999; 73:4009–4018. [PubMed: 10196297]

100. Mascola JR, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000; 6:207–210. [PubMed: 10655111]

101. Parren PW, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol. 2001; 75:8340–8347. [PubMed: 11483779]

102. Paules CI, et al. The Hemagglutinin A Stem Antibody MEDI8852 Prevents and Controls Disease and Limits Transmission of Pandemic Influenza Viruses. J Infect Dis. 2017; 216:356–365. [PubMed: 28633457]

103. Hessell AJ, et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med. 2009; 15:951–954. [PubMed: 19525965]

104. Hessell AJ, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009; 5:e1000433. [PubMed: 19436712]

105. Shingai M, et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med. 2014; 211:2061–2074. [PubMed: 25155019]

106. Julg B, et al. Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Sci Transl Med. 2017:9.

107. Deal CE, Balazs AB. Vectored antibody gene delivery for the prevention or treatment of HIV infection. Curr Opin HIV AIDS. 2015; 10:190–197. [PubMed: 25700206]

108. Johnson PR, et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med. 2009; 15:901–906. Initial report of vectored prophylaxis applied in macaques. [PubMed: 19448633]

109. Gardner MR, et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature. 2015; 519:87–91. Extreme breadth for an engineered antibody molecule incorporating novel features. [PubMed: 25707797]

110. Balazs AB, et al. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 2011; 481:81–84. Development of vectored immunoprophylaxis for HIV. [PubMed: 22139420]

111. Saunders KO, et al. Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. J Virol. 2015; 89:5895–5903. [PubMed: 25787288]

112. Flingai S, et al. Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy. Sci Rep. 2015; 5:12616. [PubMed: 26220099]

113. Muthumani K, et al. Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab. Human vaccines & immunotherapeutics. 2013; 9:2253–2262. [PubMed: 24045230]

114. Pardi N, et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat Commun. 2017; 8:14630. [PubMed: 28251988]

115. Nault JC, et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet. 2015; 47:1187–1193. [PubMed: 26301494]

116. Gao G, et al. Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood. 2004; 103:3300–3302. [PubMed: 14695227]

117. Tjelle TE, et al. Monoclonal antibodies produced by muscle after plasmid injection and electroporation. Mol Ther. 2004; 9:328–336. [PubMed: 15006599]

118. Hu J, Robinson JL. Treatment of respiratory syncytial virus with palivizumab: a systematic review. World J Pediatr. 2010; 6:296–300. [PubMed: 21080142]

119. Barouch DH, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 2013; 503:224–228. Surpisingly effective monotherapy of SHIV infection in macaques. [PubMed: 24172905]

120. Horwitz JA, et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci U S A. 2013; 110:16538–16543. [PubMed: 24043801]

121. Poignard P, et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity. 1999; 10:431–438. [PubMed: 10229186]

122. Caskey M, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015; 522:487–491. First use of a super-antibody in HIV infection in humans. [PubMed: 25855300]

123. Scheid JF, et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature. 2016; 535:556–560. [PubMed: 27338952]

124. Caskey M, et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat Med. 2017; 23:185–191. [PubMed: 28092665]

125. Lynch RM, et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med. 2015; 7:319ra206.

126. Bar KJ, et al. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. The New England journal of medicine. 2016; 375:2037–2050. [PubMed: 27959728]

127. Schoofs T, et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science. 2016; 352:997–1001. Super-antibody HIV therapy appears to enhance host immune responses generally. [PubMed: 27199429]

128. Zeitlin L, et al. Monoclonal antibody therapy for Junin virus infection. Proc Natl Acad Sci U S A. 2016; 113:4458–4463. [PubMed: 27044104]

129. Qiu X, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014; 514:47–53. First demonstration of successful antibody therapy against established Ebola virus disease in non-human primates. [PubMed: 25171469]

130. Van Heeke G, et al. Nanobodies(R) as inhaled biotherapeutics for lung diseases. Pharmacol Ther. 2017; 169:47–56. [PubMed: 27373507]

131. Schepens B, et al. Nanobodies(R) specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. J Infect Dis. 2011; 204:1692–1701. [PubMed: 21998474]

132. Detalle L, et al. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrobial agents and chemotherapy. 2015; 60:6–13. [PubMed: 26438495]

133. Rossey I, et al. Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. Nat Commun. 2017; 8:14158. Use of single-domain antibody against RSV. [PubMed: 28194013]

134. Hinton PR, et al. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem. 2004; 279:6213–6216. [PubMed: 14699147]

135. Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2006; 281:23514–23524. [PubMed: 16793771]

136. Zalevsky J, et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. 2010; 28:157–159. [PubMed: 20081867]

137. Yu XQ, et al. Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults. Antimicrobial agents and chemotherapy. 2017:61.

138. Ko SY, et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature. 2014; 514:642–645. [PubMed: 25119033]

139. Gautam R, et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature. 2016; 533:105–109. [PubMed: 27120156]

140. Lazar GA, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A. 2006; 103:4005–4010. [PubMed: 16537476]

141. Presta LG. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol. 2008; 20:460–470. Review of strategies for enhancing antibody effector function. [PubMed: 18656541]

142. Bowers PM, et al. Coupling mammalian cell surface display with somatic hypermutation for the discovery and maturation of human antibodies. Proc Natl Acad Sci U S A. 2011; 108:20455–20460. [PubMed: 22158898]

143. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol. 1997; 15:553–557. [PubMed: 9181578]

144. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature. 1990; 348:552–554. [PubMed: 2247164]

145. Huse WD, et al. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science. 1989; 246:1275–1281. [PubMed: 2531466]

146. Lee EC, et al. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. Nat Biotechnol. 2014; 32:356–363. [PubMed: 24633243]

147. Murphy AJ, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A. 2014; 111:5153–5158. [PubMed: 24706856]

148. Scheid JF, et al. A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods. 2009; 343:65–67. [PubMed: 19100741]

149. Lanzavecchia A, Corti D, Sallusto F. Human monoclonal antibodies by immortalization of memory B cells. Curr Opin Biotechnol. 2007; 18:523–528. [PubMed: 18063358]

150. Huang J, et al. Isolation of human monoclonal antibodies from peripheral blood B cells. Nat Protoc. 2013; 8:1907–1915. [PubMed: 24030440]

151. Lee JH, et al. A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic beta-Hairpin Structure. Immunity. 2017; 46:690–702. [PubMed: 28423342]

152. McCoy LE, Burton DR. Identification and specificity of broadly neutralizing antibodies against HIV. Immunol Rev. 2017; 275:11–20. [PubMed: 28133814]

153. Dreyfus C, et al. Highly conserved protective epitopes on influenza B viruses. Science. 2012; 337:1343–1348. [PubMed: 22878502]

154. Corti D, et al. Tackling influenza with broadly neutralizing antibodies. Current opinion in virology. 2017; 24:60–69. [PubMed: 28527859]

155. Wu NC, Wilson IA. A Perspective on the Structural and Functional Constraints for Immune Evasion: Insights from Influenza Virus. Journal of molecular biology. 2017; 429:2694–2709. [PubMed: 28648617]

156. Wen X, et al. Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus. Nature microbiology. 2017; 2:16272.

Figure 1. Technologies for monoclonal antibody generation

a) Combinatorial display libraries. Human antibody heavy and light chain genes are amplified by PCR, and antibody fragments are displayed on the surface of a particle or cell in which the antibody genes are found (such as phage, yeast or mammalian cells[142–145]). Successive rounds of enrichment are performed to select for clones that bind to the target antigen. Genes encoding antibodies of interest are cloned into human IgG expression vectors to produce monoclonal antibodies (mAbs). b) Human immunoglobulin transgenic mice are generated by introducing human immuoglobulin loci into the mouse genome[146,147]. Upon immunization, the transgenic mice produce fully human antigen-specific antibodies. The B cells harvested from the immunized mice are fused with myeloma cells to generate antibody-secreting hybridomas, which are then screened for binding or functional activity. c) Single B cell cloning. Antigen-specific memory B cells or plasmablasts are single-cell sorted by flow cytometry and cognate heavy and light chain variable genes are amplified by RT-PCR[57,58,148]. The antibody variable genes are cloned into human IgG expression vectors to produce mAbs. d) Memory B cell immortalization. Memory B cells are immortalized by Epstein–Barr virus and B cell culture supernatants are screened for binding or functional activity[149]. Positive cultures are sub-cloned by limiting dilution. e) Memory B cell culture. Single B cells are activated and cultured, and B cell supernatants are screened for binding or functional activity[37,150]. Antibody variable genes are amplified from clones of interest by PCR and cloned into human IgG expression vectors to produce mAbs.

Figure 2. Structures of super-antibodies bound to their target antigens
a) Cryoelectron microscopy structure of the broadly neutralizing anti-HIV-1 antibody
PGT145 in complex with a recombinant HIV envelope trimer[151]. PGT145 binds to a glycan-
dependent quaternary epitope at the trimer apex[152]. b) Crystal structure of the influenza
virus group 1/group 2 neutralizing antibody CR9114 in complex with influenza virus
haemagglutinin (HA)[153]. CR9114 recognizes a highly conserved epitope in the HA
stem[154,155]. c) Crystal structure of the respiratory syncytial virus (RSV) and human
metapneumovirus (HMPV) cross-neutralizing antibody MPE8 in complex with a stabilized
RSV prefusion fusion glycoprotein trimer[156]. d) Crystal structure of the Zika virus and
dengue virus cross-neutralizing antibody C8 in complex with a soluble Zika virus envelope
ectodomain[85]. C8 targets a quaternary epitope that bridges two envelope protein subunits.

Table 1

Anti-viral SuperAbs

Virus	Prototypic SuperAb	Similar antibodies*	Antigenic region	Antibody isolation technology
HIV	PG9, PGT145	PG16, PGT141-144, CH01-04, PGDM1400–1412, CAP256-VRC26.01-12	V2 apex	Human B cell isolation
	VRC01	VRC02, VRC03, 8ANC131, 8ANC134, NIH45-46, 3BNC60, BNC62, 3BNC117, 12A12, 12A21,12A30, VRC-PG04, VRC-CH31, VRC27, VRC07-523, N6	CD4 binding site	Human B cell isolation
	PGT121, PGT128, PGT135	PGT122, PGT123, PGT125-PGT127, PGT130, PGT131, PGT136, PGT137, 10-1074	V3 glycan	Human B cell isolation
	PGT151, 35O22, 8ANC195	PGT152-158, ACS202, N123-VRC34.01	gp120/gp41 interface	Human B cell isolation
	10E8		MPER	Human B cell isolation
Influenza	C05	F045-092, 641 I-9	HA head	Human B cell isolation, phage display
	FI6	MEDI8852, CR9114, 39.29, 81.39, CT149, 56.a.09, 31.b.09, 16.a.26, 31.a.83	HA stem	Human B cell isolation
RSV/HMPV	MPE8	ADI-14448, 25P13	Site III	Human B cell isolation
RSV	D25	D25, AM22, 5C4, ADI-15618	Site ø	Human B cell isolation
HCMV	9I6, 8I21	1F11, 2F4, 6G4	Pentameric complex	Human B cell isolation
Rabies	RVC58		Site III	Human B cell isolation
	RVC20		Site I	Human B cell isolation
Dengue/Zika	A11, C8	A11, C8, C10, B2, B7, C4	E-dimer interface	Human B cell isolation
	Z004	Z028, Z001, Z006, Z010, Z031, Z035, Z038, Z014, ZKA-190, ADI-24192, ADI-24232, ADI-24227, ADI-24238	DIII lateral ridge	Human B cell isolation
Ebola	ADI-15878	6D6, ADI-15742, CA45, FVM09	Fusion loop	Human or macaque B cell isolation
MERS	LCA60, REGN3051, REGN3048		Receptor-binding domain	Human B cell isolation, humanized mice
Lassa virus	8.9F		Quaternary GPC-C epitope	Human B cell isolation
	37.2D	25.6A	Quaternary GPC-B epitope	Human B cell isolation
	25.10C, 12.1F		Quaternary GPC-A epitope	Human B cell isolation

*
This list of antibodies is not exhaustive and is caveated by the fact that different neutralization assays can give different results.

Table 2

Anti-viral mAbs in clinical development

Antibody	Virus	Antibody isolation technology	Target	Stage of development	Manufacturer	Indication
Porgaviximab	Ebola	Immunization/Chimerization	Viral envelope glycoprotein	Phase I/II	Mapp Biopharmaceutical; LeafBio	Post-exposure treatment of Ebola virus infection
MBL HCV1	HCV	Humanized mice	HCV E2 glycoprotein	Phase II	MassBiologics	Prevention of HCV recurrence in patients receiving a liver transplant
PRO 140	HIV	Immunization/Humanization	CCR5	Phase III	Progenics Pharmaceuticals	Treatment of HIV-1 infection
Ibalizumab	HIV	Immunization/Humanization	CD4	Phase III	TaiMed Biologics	Treatment of HIV-1 infection
UB 421	HIV	Immunization/Humanization	CD4	Phase II	United Biomedical	Treatment of HIV-1 infection
VRC01-LS	HIV	Human B cell isolation	HIV gp120	Phase I	National Institute of Allergy and Infectious Diseases	Prevention of HIV-1 infection
VRC01	HIV	Human B cell isolation	HIV gp120	Phase I	National Institute of Allergy and Infectious Diseases	Treatment of HIV-1 infection
3BNC117-LS	HIV	Human B cell isolation	HIV gp120	Phase I	Rockefeller University	Treatment of HIV-1 infection
10-1074 and 3BNC117	HIV	Human B cell isolation	HIV gp120	Phase I	Rockefeller University	Treatment of HIV-1 infection
PGT121	HIV	Human B cell isolation	HIV gp120	Phase I	International AIDS Vaccine Initiative	Treatment and prevention of HIV-1 infection
PGDM1400 and PGT121	HIV	Human B cell isolation	HIV gp120	Phase I	International AIDS Vaccine Initiative	Treatment and prevention of HIV-1 infection
MB 66	HIV/HSV	Human B cell isolation	HIV gp120, HSV glycoprotein D	Phase I	Mapp Biopharmaceutical	Prevention of HIV-1 and HSV sexual transmission
VIS 410	Influenza	Unknown	Influenza hemagglutinin	Phase II	Visterra	Treatment and prevention of influenza A virus infection

Antibody	Virus	Antibody isolation technology	Target	Stage of development	Manufacturer	Indication
MHAA 4549A	Influenza	Human B cell isolation	Influenza virus haemagglutinin	Phase II	Genentech	Treatment of influenza A virus infection
CT P27	Influenza	Human B cell isolation	Influenza virus haemagglutinin	Phase II	Celltrion	Treatment and prevention of influenza A virus infection
Diridavumab	Influenza	Phage display	Influenza virus haemagglutinin	Phase II	National Institute of Allergy and Infectious Diseases	Treatment and prevention of influenza A virus infection
CR8020	Influenza	Human B cell isolation	Influenza virus haemagglutinin	Phase II	Crucell	Treatment and prevention of influenza A virus infection
RG 6024	Influenza	Human B cell isolation	Influenza virus haemagglutinin	Phase I	Genentech	Treatment of influenza B virus infection
MEDI 8852	Influenza	Human B cell isolation	Influenza virus haemagglutinin	Phase II	MedImmune	Treatment of influenza A virus infection
TCN 032	Influenza	Human B cell isolation	Influenza M2e protein	Phase II	Theraclone Sciences; Zenyaku Kogyo	Treatment of influenza A virus infection
m 102.4	Nipah and Hendra virus	Phage display	Viral envelope glycoprotein G	Phase I	Profectus Biosciences, Inc.	Prevention and treatment of Nipah and Hendra virus infections
Rabimabs	Rabies	Immunization	Viral envelope G protein	Phase I/II	World Health Organization; Zydus Cadila	Treatment and prevention of rabies
RAB-1	Rabies	Humanized mice	Viral envelope G protein	Approved	Serum Institute of India; MassBiologics	Post-exposure prophylaxis of rabies
Foravirumab	Rabies	Phage display, Human B cell isolation	Viral envelope G protein	PhaseII/III	Crucell; Sanofi Pasteur	Post-exposure prophylaxis of rabies
Palivizumab	RSV	Immunization/Humanization	Viral fusion protein	Approved	MedImmune	Prophylaxsis in high-risk infants
MEDI 8897	RSV	Human B cell isolation	Viral fusion protein	Phase II	MedImmune	Prophylaxsis in high-risk infants